10.06.2016 • NewsDede WillamsLonzaBIO

Lonza to Produce Bluebird Bio Drug

Lonza Houston, part of the Swiss-based life sciences group Lonza, has signed a strategic manufacturing agreement with bluebird bio, a Cambridge, Massachusetts-based clinical-stage company specializing in gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer. As part of the multi-year pact, Lonza will produce the US biotech firm’s Lenti-D and LentiGlobi drug candidates. This will entail completing the suite design, construction and validation along with process validation prior to anticipated commercial launch.

Lenti D is currently in a Phase 2/3 study, the Starbeam Study for treatment of cerebral adrenoleukodystrophy, and LentiGlobi BB305 is currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease.

The production agreement for the two drug candidates follows what the companies said is a “successful multi-year clinical manufacturing relationship.” It will offer bluebird a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility, currently under construction. The new facility will concentrate on clinical and commercial supply of viral vectors and virally-modified cell therapy products.

“This new strategic relationship with bluebird bio is an example of Lonza’s ability to be a long-term commercial partner to the cell & viral therapy industry,” said Marc Funk, COO, Lonza’s Pharma & Biotech segment.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.